BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:21 PM
 | 
Feb 10, 2010
 |  BC Extra  |  Top Story

Isis falls after mipomersen data

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) fell $2.06 (19%) to $8.98 on Wednesday after mipomersen met the primary endpoint in the Phase III RADICHOL II trial to treat heterozygous familial hypercholesterolemia (heFH) but produced elevated alanine transaminase (ALT) levels in 12 of 83 patients. Isis and partner Genzyme Corp. (NASDAQ:GENZ) said once-weekly subcutaneous mipomersen met the primary...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >